Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Telithromycin in the treatment of community-acquired pneumonia: A pooled analysis
Respiratory Medicine, Volume 97, No. 6, Year 2003
Notification
URL copied to clipboard!
Description
The efficacy of telithromycin has been assessed in six Phase III studies involving adults with mild to moderate community-acquired pneumonia (CAP) with a degree of severity compatible with oral therapy. Patients received telithromycin 800 mg once daily for 7-10 days in three open-label studies (n=870) and three randomized, double-blind, comparator-controlled studies (n=503). Comparator antibacterials were amoxicillin 1000 mg three-times daily, clarithromycin 500 mg twice daily and trovafloxacin 200 mg once daily. Clinical and bacteriological outcomes were assessed 7-14 days post-therapy. Among telithromycin-treated patients, per-protocol clinical cure rates were 93.1 and 91.0% for the open-label and comparative studies, respectively. Telithromycin treatment was as effective as the comparator agents. High eradication and clinical cure rates were observed for infections caused by key pathogens: Streptococcus pneumoniae including isolates resistant to penicillin G and/or erythromycin A (95.4%), Haemophilus influenzae (89.5%) and Moraxella catarrhalis (90%). Telithromycin was also highly effective in patients with infections caused by atypical and/or intracellular pathogens and those at increased risk of morbidity. Telithromycin was generally well tolerated. Telithromycin 800 mg once daily for 7-10 days offers a convenient and well-tolerated first-line oral therapy for the empirical treatment of mild to moderate CAP. © 2003 Elsevier Science Ltd. All rights reserved.
Authors & Co-Authors
Hagberg, Lars
Sweden, Gothenburg
Sahlgrenska Universitetssjukhuset
Carbón, Claude
Switzerland, Lausanne
Centre Hospitalier Universitaire Vaudois
Van Rensburg, D. J.
South Africa
Medpark Centre
Fogarty, Charles M.
United States, Spartanburg
Spartanburg Pharmaceutical Research
Dunbar, L.
United States, New Orleans
University Medical Center new Orleans
Pullman, John
Unknown Affiliation
Statistics
Citations: 32
Authors: 6
Affiliations: 5
Identifiers
Doi:
10.1053/rmed.2003.1492
ISSN:
09546111
Research Areas
Disability
Health System And Policy